Tumor immunology - When a cancer cell meets the immune cells

Journal of the Formosan Medical Association

Volumn 98, Issue 11, 1999, Pages 730-735

  Sheu, Bor Ching ^a   Hsu, Su Ming ^a   Ho, Hong Nerng ^a   Lin, Rong Hwa ^a   Huang, Su Cheng ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Immune escape; Immune surveillance; Tumor immunology

Indexed keywords

TUMOR ANTIGEN;

ANTIGEN EXPRESSION; CANCER CELL; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOSURVEILLANCE; MALIGNANT TRANSFORMATION; RECEPTOR DOWN REGULATION; REVIEW; TASK PERFORMANCE; TUMOR IMMUNOLOGY;

ANTIGENS, NEOPLASM; CYTOKINES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNE TOLERANCE; KILLER CELLS, NATURAL; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASMS;

EID: 0033383030     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Herberman RB: Cellular immunity. In: Mendelsohn J, ed. The Molecular Basis of Cancer. Philadelphia: WB Saunders, 1995:511-21.
2. Shu S, Plautz GE, Krauss JC, et al: Tumor immunology. JAMA 1997;278:1972-81.
3. Chouaib S, Asselin-Paturel C, Mami-Chouaib F, et al: The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol Today 1997;18: 493-7.
4. Wang RF: Tumor antigens discovery: perspectives for cancel therapy. Mol Med 1997;3:716-81.
5. Armstrong TD, Pulaski BA. Ostrand-Rosenberg S: Tumor antigen presentation: changing the rules. Cancer Immunol Immunother 1998;46:70-4.
6. Pawelec G, Zeuthen J, Kiessling R: Escape from host-antitumor immunity. Crit Rev Oncog 1997;8:111-41.
7. Scott AM, Cebon J: Clinical promise of tumour immunology. Lancet 1997;349(suppl 2):SII19-22.
8. Restifo NP, Esquivel F, Kawakami Y, et al: Identification of human cancers deficient in antigen processing. J Exp Med 1993;177:265-72.
9. Chen L: Immunological ignorance of silent antigens as an explanation of tumor evasion. Immunol Today 1998;19: 27-30.
10. Packard BZ, Komoriya A: Tumor cell recognition by lymphocytes: is the MHC always essential? Cit Rev Immunol 1998;18:139-44.
11. Garrido F, Ruiz-Cabello F, Cabrera T, et al: Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 1997; 18:89-95.
12. Seliger B, Höhne A, Knuth A, et al: Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression. Cancer Res 1996;56:1756-60.
13. Ockert D, Schmitz M, Hampl M, Reiber EP, et al: Advances in cancer immunotherapy. Immunol Today 1999; 20:63-5.
14. Kern DE, Klarnet JP, Jensen MCV, et al: Requirement for recognition of class II and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL. J Immunol 1986;136:4303-10.
15. Greenberg PD: Adoptive T cells therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 1991;49:281-355.
16. + tumor cells are potent vaccines for stimulating tumor rejection on tumor-bearing mice. J Exp Med 1995;181:619-29.
17. Cheng TY, Wu JT, Lin RH: Induction of tumor-specific T cell response by cognating tumor cells with foreign antigen-primed Th cells. Int Immunol 1998;10: 1397-406.
18. Chang HL, Gillett N, Figari I, et al: Increased transforming growth factor β expression inhibits cell proliferation in vitro, yet increases tumorigenicity and tumor growth of Meth A carcinoma cells. Cancer Res 1993;53:4391-8.
19. Torre-Amione G, Beauchamp DR, Koeppen H, et al: A highly immunogenic tumor transfected with a murine transforming growth factor type β1 cDNA escapes immune surveillance. Proc Natl Acad Sci USA 1990;87:1486-90.
20. Voorzanger N, Touitou R, Garcia E, et al: Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors. Cancer Res 1996;56:5499-505.
21. Ebert EC, Roberts AI, Devereux D, et al: Selective immunosuppressive action of a factor produced by colon cancer cells. Cancer Res 1990;50:6158-61.
22. Coventry BJ, Weeks SC, Heckford SE, et al: Lack of IL-2 cytokine expression despite IL-2 messenger RNA transcription in tumor-infiltrating lymphocytes in primary human breast carcinoma - selective expression of early activation markers. J Immunol 1996;156:3486-92.
23. Kolenko V, Wang Q, Riedy MC, et al: Tumor-induced suppression of T lymphocyte proliferation coincides with inhibition of Jak3 expression and IL-2 receptor signaling: role of soluble products from renal cell carcinomas. J Immunol 1997;159:3057-67.
24. Sheu BC, Lin RH, Ho HN, et al: Down-regulation of CD25 expression on activated tumor-infiltrating lymphocytes derived from human cervical carcinoma, Hum Immunol 1997;56:39-47.
25. Walker PR, Saas P, Dietrich PY: Role of Fas ligand (CD95L) in immune escape. The tumor cell strikes back. J Immunol 1997;158:4521-4.
26. Griffith TS, Ferguson TA: The role of FasL-induced apoptosis in immune privilege. Immunol Today 1997;18:240-4.
27. Walker PR, Saas P, Dietrich PY: Tumor expression of Fas ligand (CD95L) and the consequences. Cur Opin Immunol 1998;10:564-72.
28. Chappell DB, Restifo NP: T cell-tumor cell: a fatal interaction? Cancer Immunol Immunother 1998;47:65-71.
29. Whiteside TL, Rabinowich H: The role of Fas/FasL in immunosuppression induced by human tumors. Cancer Immunol Immunother 1998;46:175-84.
30. Cai Z, Bettaieb A, Mahdani NE, et al: Alteration of the sphingomyelin/ceramide pathway is associated with resistance of human breast carcinoma MCF7 cells to tumor necrosis factor-alpha-mediated cytotoxicity. J Biol Chem 1997;272:6918-26.
31. Cai Z, Stancou R, Korner M, et al: Impairment of Fas-antigen expression in adriamycin-resistant but not TNF-resistant MCF7 tumor cells. Int J Cancer 1996;68:535-46.
32. Hernberg M, Turunen JP, Muhonen T, et al: Tumor-infiltrating lymphocytes in patients with metastatic melanoma receiving chemoimmunotherapy. J Immunother 1997;20:488-95.
33. - cells in tumor-infiltrating lymphocytes of renal cell carcinoma associated with tumor progression. Eur Urol 1992; 22:323-8.
34. Yoshino I, Yano T, Murata M, et al: Phenotypes of lymphocytes infiltrating non-small cell lung cancer tissues and its variation with histological types of cancer. Lung Cancer 1993;10:13-9.
35. Waldmann, TA: The IL-2/IL-2 receptor system: a target for rational immune intervention. Immunol Today 1993; 14:264-9.
36. Sheu BC, Hsu SM, Ho HN, Lin RH, Torng PL, Huang SC: Reversed CD4/CD8 ratios of tumor-infiltrating lymphocytes correlate with disease progression in human cervical cancer. Cancer 1999;86:1537-43.
37. Cayeux S, Richter C, Becker C, et al: Influence of gene-modified (IL-7, IL-4, and B7) tumor cell vaccines on tumor antigen presentation. J Immunol 1997;158: 2834-42.
38. Gimmi CD, Freeman GJ, Gribben JG, et al: Human T-cell clone anergy induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci USA 1993; 90:6586-90.
39. + T cells by B7-transfected melanoma cells. Science 1993;259:368-70.
40. Chen L, Linsley PS, Hellström KE: Costimulation of T cells for tumor immunity. Immunol Today 1993;14: 483-6.
41. Leach DR, Krummel MF, Allison JP: Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271:1734-6.
42. Yee C, Riddell SR, Greenberg PD: Prospects for adoptive T cell therapy. Cur Opin Immunol 1997;9:702-8.
43. Vitetta ES, Uhr JW: Monoclonal antibodies as agonists: an expanded role for their use in cancer therapy. Cancer Res 1994;54:5301-9.
44. Mack M, Riethmüller G, Kufer P: A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci USA 1995;92:7021-5.
45. Dranoff G, Jaffee E, Lazenby A, et al: Vaccination with irradiated tumor cells engineered to secret murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific and long-lasting antitumor immunity. Proc Natl Acad Sci USA 1993;90:3539-43.
46. Wojtowicz-Praga S: Reversal of tumor-induced immunosuppression: a new approach to cancer therapy. J Immunother 1997;20:165-77.
47. Colombo MP, Forni G: Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol Today 1994;15:48-51.
48. Stauss HJ: Immunotherapy with CTLs restricted by nonself MHC. Immunol Today 1999;20:180-3.
49. Bona CA, Casares S, Brumeanu TD: Towards development of T-cell vaccines. Immunol Today 1998;19:126-32.
50. Finke J, Ferrone S, Frey A, et al: Where have all the T cells gone? Mechanisms of immune evasion by tumors. Immunol Today 1999;20:158-60.